Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699153 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
A Phase 3 study of Ocular Inflammation, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT00699153 is a Phase 3 study of Ocular Inflammation that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00699153, a Phase 3 study of Ocular Inflammation, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
Conditions Studied
Interventions
- DRUG Loteprednol Etabonate
- DRUG Vehicle of Ophthalmic Loteprednol Etabonate
Study Locations (1)
North Carolina
- Cornerstone Eye Wear - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00699153
The ClinicalTrials.gov registry entry for NCT00699153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ocular Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Loteprednol Etabonate is the first listed.
NCT00699153 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00699153 about?
NCT00699153 is a clinical study titled "Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery". Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
What is the current status of trial NCT00699153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2008-06. Estimated completion is 2009-06.
What conditions does trial NCT00699153 study?
This clinical trial studies the following conditions: Ocular Inflammation.
What interventions are being tested in trial NCT00699153?
The interventions under investigation include: Loteprednol Etabonate (DRUG), Vehicle of Ophthalmic Loteprednol Etabonate (DRUG).
Who is sponsoring clinical trial NCT00699153?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699153 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.